检索结果-南通市图书馆

磨粒有序多孔立方氮化硼砂轮高效磨削高温合金烧伤研究

在线全文

学校读者我要写书评

暂无评论

金刚石与磨料磨具工程 2014年第3期34卷 10-15页

作者：陈珍珍徐九华丁文锋马昌玉傅玉灿南京航空航天大学机电学院南京210016

针对高温合金高效磨削过程中存在磨削烧伤问题,基于氧化铝空心球造孔与高温钎焊技术,研制了多层磨粒有序排布的多孔立方氮化硼(Cubic Boron Nitride,简称CBN)砂轮,开展了高效磨削GH4169镍基高温合金试验研究,分析了缓进给磨削中工件表... 详细信息

针对高温合金高效磨削过程中存在磨削烧伤问题,基于氧化铝空心球造孔与高温钎焊技术,研制了多层磨粒有序排布的多孔立方氮化硼(Cubic Boron Nitride,简称CBN)砂轮,开展了高效磨削GH4169镍基高温合金试验研究,分析了缓进给磨削中工件表面突发性烧伤特征,并提出采用添加石墨导流块来抑制工件烧伤策略。研究结果表明:添加石墨块导流后,缓进深切磨削砂轮最大材料去除率可提高3倍以上。当切深为0.2mm时,高速磨削时砂轮最大材料去除率可达20mm3/(mm·s)。当材料去除率为2mm3/(mm·s)时,随着磨削速度增大,磨削温度先下降后上升,当vs=80m/s时磨削温度最低。越过临界速度100m/s,磨削温度则呈下降趋势。

关键词：多层磨粒有序多孔CBN砂轮高效磨削镍基高温合金烧伤磨削温度

Ag-Cu-Ti/TiC复合钎料钎焊细粒度金刚石的研究

在线全文

学校读者我要写书评

暂无评论

人工晶体学报 2013年第8期42卷 1509-1514页

作者：丁兰英傅玉灿陈燕苏宏华向孙祖徐九华徐鸿钧南京航空航天大学机电学院南京210016 南京农业大学工学院南京210031

在Ag-Cu-Ti合金中加入一定量的TiC颗粒制成复合钎料,进行细粒度金刚石磨粒与45钢基体的真空钎焊实验。运用三维视频显微镜、扫描电镜和X射线衍射仪分析TiC颗粒、Ag-Cu-Ti合金和金刚石磨粒之间的结合界面。结果表明:TiC颗粒能有效降低试... 详细信息

在Ag-Cu-Ti合金中加入一定量的TiC颗粒制成复合钎料,进行细粒度金刚石磨粒与45钢基体的真空钎焊实验。运用三维视频显微镜、扫描电镜和X射线衍射仪分析TiC颗粒、Ag-Cu-Ti合金和金刚石磨粒之间的结合界面。结果表明:TiC颗粒能有效降低试验工艺下Ag-Cu-Ti合金在基体表面的流动性和结晶时产生的隆起,复合钎料在基体表面分布更趋平整,有利于细粒度金刚石钎焊等高性的控制;适量TiC颗粒在结合剂层中的均匀分布,能显著细化结合剂层的显微组织;复合钎料中添加TiC颗粒在实现细粒度金刚石磨粒与钢基体钎焊连接的同时,有效抑制了钎料合金对细粒度金刚石磨粒过度浸润所造成切削刃的包裹,保证了细粒度金刚石磨粒良好的出露。

关键词： TiC颗粒细粒度金刚石磨粒 Ag-Cu—Ti合金界面

Malnutrition and Quality of Life in Chinese cancer Patients: a Clinical Study of 23,994 subjects

在线全文

学校读者我要写书评

暂无评论

Journal of Nutritional Oncology 2021年第1期6卷 16-32页

作者： hong Xia xu Chun hua Song zhen Ming fu Chang Wang Zeng Qing Guo yuan Lin Ying Ying Shi wen Hu Yi Ba su Yi Li Zeng Ning Li Kun hua Wang Jing Wu Ying He Jia Jun Yang Cong hua Xie fu Xiang Zhou Xin Xia Song Gong Yan chen wen Jun Ma su Xia Luo Zi hua chen Ming hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi yu Mei Qi Hai Ping Jiang wen Xian Guan Jun Qiang chen Jia Xin chen yu Fang Lan Zhou Yong Dong feng Rong Shao Tan Tao Li Jun wen Ou Qing Chuan Zhao Jian Xiong Wu Min weng Qing hua Yao jiu Wei Cui Wei Li Han Ping Shi the Investigation on Nutrition Status and Clinical Outcome of Common cancers(INSCOC)Group Department of Nutrition Daping Hospital&Research Institute of SurgeryThird Military Medical UniversityChongqing 400042China Department of Epidemiology College of Public HealthZhengzhou UniversityZhengzhou 450001HenanChina cancer Center Renmin Hospital of Wuhan UniversityWuhan 430060HubeiChina cancer Center of the First Hospital of Jilin University Changchun 130021JilinChina Department of Medical Oncology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhou 350014FujianChina Department of Gastrointestinal surgery Cancer Hospital Affiliated to Guangxi Medical UniversityNanning 530021GuangxiChina Department of surgery The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080GuangdongChina Department of Clinical Nutrition West China Hospital of Sichuan UniversityChengdu 610041SichuanChina Department of Gastrointestinal Oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjin Key Laboratory of Cancer Prevention and TherapyTianjin 300060China Department of Nutrition and Metabolism of Oncology Affiliated Provincial Hospital of Anhui Medical UniversityHefei 230031AnhuiChina Department of Clinical Nutrition the First Hospital of Hebei Medical UniversityShijiazhuang 050031HebeiChina Department of Gastrointestinal surgery Institute of Gastroenterologythe First Affiliated Hospital of Kunming Medical University 650032KunmingYunnanChina Department of Clinical Nutrition the First People's Hospital of KashiKashi 844000XinjiangChina Department of Clinical Nutrition Chongqing General HospitalChongqing 400014China Department of Colorectal and Anal surgery Huizhou Municipal Central HospitalHuizhou 516001GuangdongChina Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 430071HubeiChina Department of Oncology Xingtai People’s HospitalHebei Medical UniversityXingtai 054031HebeiChina Harbin Medical University cancer Hospital Harbin 150085HeilongjiangChina

Background Malnutrition is common in patients with cancer,and can negatively impact their quality of life(QoL)and even ***,there is currently no large data available on the prevalence of malnutrition in Chinese cancer *** study evaluated the prevalence of malnutrition and the QoL of Chinese patients with locoregional,recurrent or metastatic *** We conducted a nationwide observational,multi-center,hospital-based cross-sectional study within the Chinese Society of Nutritional Oncology(CSNO)*** of the patients were diagnosed with one of the following 18 different types of malignant tumors:lung cancer,gastric cancer,liver cancer,colorectal cancer,breast cancer,esophageal cancer,cervical cancer,endometrial cancer,nasopharyngeal carcinoma,malignant lymphoma,leukemia,pancreatic cancer,ovarian cancer,prostate cancer,bladder cancer,brain cancer,biliary tract malignant tumors or gastrointestinal stromal *** patients were enrolled from 72 hospitals located in different regions of *** patients’nutritional status was evaluated based on the body mass index(BMI),loss of bodyweight,laboratory measurements and patient generated-subjective global assessment(PG-SGA)*** cancer patients’physical status and QoL were assessed by the Karnofsky Performance Status(KPS)questionnaire and the European Organization for Research and Treatment of cancer(EORTC)QLQ-C30 questionnaire,*** From December 2013 to April 2016,23,994 patients hospitalized for cancer treatment(such as surgery,chemotherapy or radiotherapy)were enrolled in the *** patients included 12,494(52.9%)males and 11,124(47.1%)*** mean age was 55.8±13.7 *** proportions of patients in cancer stagesⅠ,Ⅱ,Ⅲ,Ⅳand uncertain were 11.5%,20.3%,27.5%,30.2%and 10.5%,*** the 23,994 inpatients,the proportions of patients who were underweight(BMI<18.5 kg/m2),normal(18.5 kg/m2

关键词： Nutritional status Nutritional assessment Malnutrition Patient generated subjective global assessment Body mass index Body weight loss Karnofsky Performance Status score Quality of life

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi su sun-Bin Ling Qiao-Nan Shan xu-Yong Wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min ding Zhi-Dan xu Lai-Bang Luo Li-Bo sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang yu-Ting He wen-Zhi Guo Liu-Gen Lan xu-Yong sun Dong chen Zhi-Shui chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-hua Zhang xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li wen-Tao Jiang Jian-hua Li Quan-Bao Zhang Ning-Qi Zhu zheng-Xin Wang Kang He Qiang Xia Shao-hua Song Zhi-Ren fu Wei Qiu Guo-yue Lv Rui-Peng Song Ji-Zhou Wang zheng Wang Jian Zhou Gang chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen zheng Xiao xu Department of Hepatobiliary and Pancreatic surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： zhenG Ying CAI Guang-yan chen Xiang-mei fu Ping chen Jiang-hua ding Xiao-qiang yu xue-qing LIN hong-li LIU Jian XIE Ru-juan WANG Li-ning NI Zhao-hui LIU fu-you YIN Ai-ping XING Chang-ying WANG Li SHI Wei LIU Jian-she HE Ya-ni ding Guo-hua LI wen-ge WU Guang-li MIAO Li-ning chen Nan su zhen MEI Chang-lin ZHAO jiu-yang GU Yong BAI yun-kai LUO Hui-min LIN Shan chen Meng-hua GONG Li YANG Yi-bin YANG Xiao-ping LI Ying WAN Jian-xin WANG Nian-song LI Hai-ying XI Chun-sheng HAO Li xu Yan FANG Jing-ai LIU Bi-cheng LI Rong-shan WANG Rong ZHANG Jing-hong WANG Jian-qin LOU Tan-qi SHAO feng-min MEI feng LIU Zhi-hong yuAN Wei-jie suN Shi-ren ZHANG Ling ZHOU Chun-hua chen Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju XIA Tian Zhong Liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's Liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

广西壮族自治区8009例妇科恶性肿瘤住院患者的构成特点及变化趋势

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华妇产科杂志 2007年第1期42卷 22-25页

作者：黄薇李力余冬青黄英兰刘燕陈心秋唐步坚徐红马刚董林红李廉邱映白桦农文政李立曾定元蒋福彦兰鹰叶元唐雄志王丹霞黎惠珍潘燕波莫爱旭吴笑彦雷志英周国萍刘翠苏庆红广西医科大学附属肿瘤医院妇瘤科南宁530021 广西医科大学第一附属医院妇产科南宁530021 广西壮族自治区人民医院妇科广西中医学院第一附属医院妇科南宁市第一人民医院妇产科南宁市第二人民医院妇产科广西壮族自治区妇幼保健医院妇科广西壮族自治区民族医院妇产科广西壮族自治区柳州市人民医院妇产科广西壮族自治区柳州市工人医院妇产科广西壮族自治区柳州市肿瘤医院妇瘤科广西壮族自治区柳州地区人民医院妇产科桂林医学院附属医院妇产科桂林市人民医院妇产科广西壮族自治区北海市第一人民医院妇产科广西壮族自治区北海市人民医院妇产科广西壮族自治区河池市第一人民医院妇产科广西壮族自治区河池市人民医院妇产科广西壮族自治区百色市人民医院妇产科右江民族医学院附属医院妇产科广西壮族自治区玉林市第一人民医院妇产科广西壮族自治区玉林市红十字会医院妇产科广西壮族自治区梧州市工人医院妇产科

目的了解广西壮族自治区近20年间妇科恶性肿瘤住院患者的构成特点及变化趋势。方法对1985—2004年间广西壮族自治区23家医院收治的8009例妇科恶性肿瘤患者的临床资料进行统计分析。结果(1)构成比:妇科恶性肿瘤中,构成比排在前4位的分别... 详细信息

目的了解广西壮族自治区近20年间妇科恶性肿瘤住院患者的构成特点及变化趋势。方法对1985—2004年间广西壮族自治区23家医院收治的8009例妇科恶性肿瘤患者的临床资料进行统计分析。结果(1)构成比:妇科恶性肿瘤中,构成比排在前4位的分别是宫颈癌、卵巢恶性肿瘤、子宫内膜癌、恶性滋养细胞肿瘤。其中,1985—1989年、2000—2004年宫颈癌住院患者的构成比呈上升的趋势,从17.48%上升到49.25%,两者比较,差异有统计学意义(P0.05)。(2)好发年龄:近10年,宫颈癌的发病年龄明显前移,从≥60岁前移到<40岁,两者比较,差异有统计意义(P<0.05)。(3)地域和职业分布:前10年宫颈癌患者主要集中于城市,构成比为67.1%;后10年却逐渐向农村转移,农村宫颈癌患者构成比达52.6%。(4)手术病理分期或临床分期:妇科恶性肿瘤患者就诊时大多数已经处于Ⅱ、Ⅲ、Ⅳ期,中晚期(Ⅲ、Ⅳ期)的构成比多在60%以上。结论(1)应重点加强对宫颈癌的普查防治工作,同时也要加大对其他妇科肿瘤的防治力度。(2)加大对相应肿瘤标志物、新的诊治方法的发现和研究力度,提高早期诊治率。

关键词：生殖器肿瘤,女(雌)性宫颈肿瘤流行病学方法

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia hua Cai wenyong Cai Wujun Cai Yijian Cai Yizhou Cai yuchen Cai Haiying Cai huacheng Cai Lorenzo Calibbi Junsong cang Guofu Cao Jianshe Cao Antoine Chance xuejun Chang yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che Bin chen Danping chen fuqing chen fusan chen Gang chen Guoming chen hua-Xing chen Huirun chen Jinhui chen Ji-yuan chen Kai chen Mali chen Mingjun chen Mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen Xiang chen Xiaoyu chen Xin chen xun chen xurong chen Ye chen Ying chen yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng huajie cheng Shan cheng Tongguang cheng yunlong Chi Pietro Chimenti wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran ding Siqin dingl Yadong ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Ⅲ期非小细胞肺癌的处理:共识与争鸣

循证医学 2022年第3期22卷 129-136页

作者：吴一龙陆舜周清华张力程颖王洁汪步海胡成平林丽珠钟文昭宋勇杨农董晓荣赵健杨海虹郭卉闫小龙刘宏旭马锐林劼刘思旸陈椿王立峰周承志周明吴芳杨学宁杜瀛瀛姚煜邵阳洪少东崔久嵬全雪萍陈蓉蓉吴佳妍张嘉涛周建娅汪斌超程超王慧娟柳菁菁邬麟黄岩匡煜坤张永昌胡洁杨衿记冯卫能苏文媚范云杨帆陈明唐可京潘燚申鹏刘安文张海波梁文华周清马智勇蔡修宇刘慧陈龙飞揣少坤单建贞郑燕芳尤长宣朱晓霞李力张同梅涂海燕林武荣张绪超周鹏辉柯尊富梁会营中国抗癌协会肺癌专业委员会广东省临床试验协会/中国胸部肿瘤研究协作组广东省人民医院、广东省医学科学院、广东省肺癌研究所广州510080 上海交通大学附属胸科医院上海200030 四川大学华西医院成都610041 中山大学肿瘤防治中心广州510060 吉林省肿瘤医院长春130021 中国医学科学院肿瘤医院北京100021 南京大学医学院附属苏北人民医院江苏扬州225001 中南大学湘雅医院长沙410008 广州中医药大学第一附属医院广州510405 东部战区总医院南京210002 湖南省肿瘤医院长沙410013 华中科技大学同济医学院附属协和医院武汉430022 广州医科大学附属肿瘤医院广州510095 广州医科大学附属第一医院广州510120 西安交通大学第一附属医院西安710061 空军军医大学唐都医院西安710038 辽宁省肿瘤医院沈阳110042 昆明医科大学第二附属医院昆明650101 福建医科大学附属协和医院福州350014 南京大学医学院附属鼓楼医院南京210008 中南大学湘雅二医院长沙410011 安徽医科大学第一附属医院合肥230022 南京世和基因生物技术股份有限公司南京210032 吉林大学白求恩第一医院长春130021 上海桐树生物科技有限公司上海200444 北京吉因加科技有限公司北京102206 福建和瑞基因科技有限公司福州350207 浙江大学医学院附属第一医院杭州310031 中山大学附属第一医院广州510080 郑州大学附属肿瘤医院/河南省肿瘤医院郑州450003 复旦大学附属中山医院上海200032 佛山市第一人民医院广东佛山528000 广东医科大学附属医院广东湛江524000 中国科学院大学附属肿瘤医院/浙江省肿瘤医院杭州310022 北京大学人民医院北京100044 南方医科大学南方医院广州510515 南昌大学附属第二医院南昌330006 广东省中医院广州510120 广州燃石医学检验有限公司广州510300 南方医科大学珠江医院广州510280 陆军军医大学大坪医院重庆400042 首都医科大学附属北京胸科医院北京101149 至本医疗科技(上海)有限公司上海201114 不详

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第19届中国肺癌高峰论坛”于2022年3月5日在广州顺利召开。此次论坛中,来自肺癌临床研究、转化性研究、基础研究的专家们围绕可切除/不可切除Ⅲ期非... 详细信息

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第19届中国肺癌高峰论坛”于2022年3月5日在广州顺利召开。此次论坛中,来自肺癌临床研究、转化性研究、基础研究的专家们围绕可切除/不可切除Ⅲ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的多学科综合治疗和生物标志物进行了深入交流和讨论,并最终达成了专家共识。

关键词： Ⅲ期非小细胞肺癌多学科综合治疗共识